Version October 2024
The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs). A preliminary evaluation has not found evidence that the use of these medicines causes suicidal thoughts or actions, but the FDA is continuing to investigate this issue. Patients should not stop taking GLP-1 RAs without consulting their health care provider. Health care providers should monitor for and advise patients using GLP-1 RAs to report new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior.
Further information may be found at https://www.fda.gov/drugs/drug-safety-and-availability/update-fdas-ongoing-evaluation-reports-suicidal-thoughts-or-actions-patients-taking-certain-type.
In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.
Semaglutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of semaglutide and inform them of symptoms of thyroid tumors (eg, a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with semaglutide.
Weight management, chronic
Note: For use as adjunct therapy with a reduced-calorie diet and increased physical activity in pediatric patients; only use in patients 12 to <18 years of age with an initial BMI in the 95th percentile or higher for age and sex or patients ≥18 years with a BMI ≥30 kg/m2 or patients with a BMI ≥27 kg/m2 and ≥1 weight-associated comorbidity (eg, dyslipidemia, hypertension, type 2 diabetes mellitus). To minimize GI effects, escalate dose slowly over at least 16 weeks to reach maintenance dose.
Children ≥12 years and Adolescents: Wegovy: SUBQ:
Dose escalation:
|
Week of Semaglutide (Wegovy) Therapy a |
Dose (mg) SUBQ Once Weekly a |
|---|---|
|
a If a dose is not tolerated, consider delaying further dose increases for 4 weeks. | |
|
Weeks 1 through 4 |
0.25 mg once weekly |
|
Weeks 5 through 8 |
0.5 mg once weekly |
|
Weeks 9 though 12 |
1 mg once weekly |
|
Weeks 13 through 16 |
1.7 mg once weekly |
|
≥Week 17 |
See maintenance dose |
Maintenance dose:
Children ≥12 years and Adolescents <18 years: Wegovy: SUBQ: 2.4 mg once weekly. Per the manufacturer, if maintenance dose of 2.4 mg is not tolerated, decrease to 1.7 mg once weekly; if the weekly dose of 1.7 mg is not tolerated, discontinue semaglutide therapy; however, in the STEP TEENS trial, patients could continue on their maximum tolerated dose (Ref).
Adolescents ≥18 years: Wegovy: SUBQ: 2.4 mg once weekly. If not tolerated, may temporarily decrease dosage to a weekly dose of 1.7 mg for up to 4 additional weeks, then increase to 2.4 mg once weekly; per the manufacturer, therapy should be discontinued in patients who cannot tolerate the 2.4 mg/week dosage.
Altered kidney function:
Children ≥12 years and Adolescents: Wegovy: SUBQ:
Mild to severe impairment: No dosage adjustment necessary. Use caution when initiating or escalating doses; new-onset acute kidney injury or worsening of existing kidney failure has been reported, most commonly in patients experiencing volume depletion from GI losses (eg, vomiting, diarrhea, dehydration).
Children ≥12 years and Adolescents: Wegovy: SUBQ: No dosage adjustment necessary.
(For additional information see "Semaglutide: Drug information")
Dosage guidance:
Clinical considerations: May require a dose reduction of insulin and/or insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia (Ref).
Diabetes mellitus, type 2, treatment (Ozempic, Rybelsus):
Note: May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed or those who cannot take metformin. May be preferred in patients who have or are at risk for atherosclerotic cardiovascular disease (Ozempic only), when weight loss is desired, and/or in patients with an HbA1c relatively far from goal (eg, HbA1c 9% to 10%) and type 1 diabetes is not likely (Ref). Consider slower dose titration in patients with diabetic retinopathy to avoid exacerbating the condition (Ref). Due to lack of additive glycemic benefit, avoid concomitant use with a dipeptidyl peptidase-4 inhibitor (Ref).
Oral: Note: Administer ≥30 minutes before the first food, beverage, or other medications of the day.
Initial: 3 mg once daily for 30 days, then increase to 7 mg once daily; may increase to 14 mg once daily after 30 days on the 7 mg dose if needed to achieve glycemic goals. Note: The lower initial dose (3 mg daily) is intended to reduce GI symptoms; it does not provide effective glycemic control.
Missed dose: Missed dose should be skipped; resume at the next scheduled dose.
SUBQ: Initial: 0.25 mg once weekly for 4 weeks, then increase to 0.5 mg once weekly. May increase to 1 mg once weekly after 4 weeks on the 0.5 mg/week dose if needed to achieve glycemic goals; may increase further to 2 mg once weekly after 4 weeks on the 1 mg/week dose if needed to achieve glycemic goals (maximum: 2 mg/week). Note: The lower initial dose (0.25 mg weekly) is intended to reduce GI symptoms; it does not provide effective glycemic control. If changing the day of administration is necessary, allow at least 48 hours between 2 doses.
Missed dose: Missed dose should be administered as soon as possible within 5 days; resume usual schedule thereafter. If >5 days have elapsed, skip the missed dose and resume administration at the next scheduled weekly dose.
Conversion from oral semaglutide to Ozempic:
If current oral dose is 7 mg once daily: There is no equivalent SUBQ dose provided in the manufacturer's labeling; some experts convert to 0.5 mg SUBQ once weekly, beginning the day after the last oral dose; monitor glucose more closely during transition (Ref).
If current oral dose is 14 mg once daily: Convert to 0.5 mg SUBQ once weekly, beginning the day after the last oral dose.
Conversion from Ozempic to oral semaglutide:
If current SUBQ dose is 0.5 mg once weekly: Convert to 7 or 14 mg orally once daily, beginning within 7 days of the last injection.
If current SUBQ dose is 1 mg once weekly: There is no equivalent oral dose provided in the manufacturer's labeling; some experts convert to 14 mg orally once daily, beginning within 7 days of the last injection (Ref).
Weight management, chronic (Wegovy):
Note: For use as an adjunct to diet and exercise in patients with a BMI ≥30 kg/m2, or in patients with a BMI ≥27 kg/m2 and ≥1 weight-associated comorbidity (eg, hypertension, dyslipidemia); may be preferred in patients with established cardiovascular disease (Ref).
SUBQ: Initiate and adjust dose using the following schedule: In patients who do not tolerate a dosage increase, consider delaying the increase for an additional 4 weeks:
Week 1 through week 4 : 0.25 mg once weekly.
Week 5 through week 8: 0.5 mg once weekly.
Week 9 through week 12: 1 mg once weekly.
Week 13 through week 16: 1.7 mg once weekly.
Week 17 and thereafter (maintenance dosage): 2.4 mg once weekly (preferred regimen); if not tolerated, may use an alternative maintenance dosage of 1.7 mg once weekly.
Note: The manufacturer recommends discontinuing therapy in patients who cannot tolerate the 1.7 mg/week dosage; however, some patients may achieve goal weight loss on a submaximal dose and may continue on the maximum tolerated dose (even if <1.7 mg/week) (Ref). Consider discontinuation if at least 5% of baseline body weight loss has not been achieved within 3 months (Ref).
Missed dose: Missed dose should be administered as soon as possible within 5 days; resume usual schedule thereafter. If >5 days have elapsed, skip the missed dose and resume administration at the next scheduled weekly dose. If 2 or more consecutive doses are missed, resume dosing as scheduled; alternatively, may reinitiate dosage adjustment schedule.
Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
Altered kidney function: Mild to severe impairment: No dosage adjustment necessary (Ref). Use caution when initiating or escalating doses; new-onset or worsening of existing renal failure has been reported, most commonly in patients experiencing volume depletion from GI losses (eg, vomiting, diarrhea, dehydration) (Ref).
Hemodialysis, intermittent (thrice weekly): Unlikely to be dialyzable (Ref): No supplemental dose or dosage adjustment necessary; use with caution due to limited clinical evidence (Ref).
Peritoneal dialysis: Unlikely to be dialyzable: No dosage adjustment necessary; use with caution due to limited clinical evidence (Ref).
No dosage adjustment necessary.
Acute kidney injury (AKI), which sometimes requires dialysis, has been reported with semaglutide and other glucagon-like peptide-1 receptor agonists. According to the manufacturer, AKI secondary to semaglutide was seen mostly in patients who had experienced nausea, vomiting, diarrhea, or dehydration. In a post-hoc analysis of multiple clinical trials, there was no difference in the incidence of acute kidney failure between semaglutide and comparators, including placebo (Ref).
Mechanism: Non–dose-related; exact mechanism is unknown. Pre-renal AKI may occur due to dehydration and volume contraction secondary to gastrointestinal symptoms (eg, nausea, vomiting, diarrhea) (Ref).
Onset: Varied; because the mechanism is thought to be related to volume contraction, timing may be dependent on gastrointestinal symptoms, initiation or dosage adjustment of concomitant medications, and/or comorbid conditions (Ref).
Risk factors:
• Volume contraction (eg, during periods of severe vomiting or diarrhea) (Ref)
• Co-administration of medications known to result in kidney injury during episodes of dehydration (eg, drugs that inhibit the renin-angiotensin system) (Ref)
• Preexisting kidney impairment
An increased incidence of diabetic retinopathy complications (DRCs) was noted during the SUSTAIN-6 study, a clinical trial evaluating the impact of SUBQ semaglutide on cardiovascular outcomes in patients with type 2 diabetes; complications included vitreous hemorrhage, onset of diabetes-related blindness, and the need for treatment with an intravitreal agent or retinal photocoagulation (Ref). In a separate analysis of SUSTAIN clinical trial data, the effect was reported to be mainly observed in patients with preexisting diabetic retinopathy (DR) and primarily attributable to the magnitude and rapidity of reduction in HbA1c during the first 16 weeks of the trial (Ref). Clinicians should note that this effect has been observed with SUBQ semaglutide, exenatide, and dulaglutide but not other glucagon-like peptide-1 receptor agonists (Ref); trials are underway to better understand the long-term effects of semaglutide on diabetic eye disease (Ref). Oral semaglutide has not been associated with an increased incidence of DRC (Ref).
Mechanism: Unknown; in general, worsening of preexisting DR is a known consequence of rapid improvement of hyperglycemia, especially in patients with uncontrolled diabetes (Ref). Although unlikely, a direct toxic effect or potential angiogenic action of semaglutide has not been ruled out (Ref).
Onset: Varied; the increased incidence of DRC during the SUSTAIN-6 study may be attributed to the reduction in HbA1c at week 16 (Ref); however, clinicians should note that DR is a progressive condition, and the onset of DRCs may vary.
Risk factors:
• Preexisting DR (Ref)
• Large (>1.5%) and rapid (≤16 weeks) decline in HbA1c (Ref)
Gallbladder disease and biliary tract disease, including cholelithiasis and cholecystitis, have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ref); some have required hospitalization or cholecystectomy (Ref). Resolution of biliary stones following discontinuation has been documented with other GLP-1 receptor agonists (eg, liraglutide) (Ref).
Mechanism: Dose- and time-related (Ref); not fully understood. Animal studies and in vitro data have demonstrated that GLP-1 enhances the proliferation and functional activity of cholangiocytes, which may result in gallbladder diseases (Ref). Some authors have postulated a change in bile acid production and secretion, suppressed secretion of cholecystokinin, decreased gallbladder emptying, prolonged gallbladder refilling, weight loss, or potentially a combination of these factors (Ref).
Onset: Varied (Ref); an increased risk was seen following >26 weeks of therapy (Ref).
Risk factors:
• Higher doses (eg, ≥1 mg SUBQ) (Ref)
• Longer duration of treatment (eg, >26 weeks) (Ref)
• Substantial or rapid weight loss
GI effects, mainly abdominal pain, constipation, diarrhea, nausea, and vomiting, are the most common adverse reactions associated with glucagon-like peptide-1 receptor agonists, including semaglutide (Ref). Decreased appetite, dysgeusia, and dyspepsia have also been reported. GI effects tend to occur during dose escalation and decrease over time (Ref); may result in treatment discontinuation.
Rates of GI effects were shown to be similar between oral and once-weekly semaglutide 1 mg (Ref); high-dose once-weekly semaglutide (2.4 mg/week) may result in higher incidences of GI effects. In the SUSTAIN-7 trial comparing once-weekly semaglutide to once-weekly dulaglutide, rates of GI effects were similar for both doses of semaglutide (0.5 mg and 1 mg) and high-dose dulaglutide (1.5 mg) (Ref). The SUSTAIN-3 trial, which evaluated once-weekly semaglutide 1 mg and once-weekly exenatide 2 mg, showed a higher rate of GI effects with semaglutide treatment (Ref).
Mechanism: Dose-related; however, the exact mechanism is not fully understood. May be a result of delayed gastric emptying or activation of centers involved in appetite regulation, satiety, and nausea (Ref).
Onset: Intermediate; nausea, vomiting, and diarrhea are most common soon after initiation (eg, the first 4 weeks of treatment) and during dose escalation (Ref).
Risk factors:
• Dose; generally greater with higher doses
• Rapid titration
Serious, immediate hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with glucagon-like peptide-1 (GLP-1) receptor agonists (Ref). Exendin-based GLP-1 receptor agonists (eg, exenatide, lixisenatide) are associated with a doubling of reporting odds of anaphylactic reaction, compared with human-analogue GLP-1 receptor agonists (eg, liraglutide, dulaglutide, semaglutide) (Ref).
Mechanism: Non–dose-related; immunologic
Immediate hypersensitivity reactions: IgE-antibodies are formed against a drug allergen following initial exposure (Ref).
Onset: Immediate hypersensitivity reactions: Rapid; generally occurs within 1 hour of administration but may occur up to 6 hours after exposure (Ref).
Risk factors:
• Cross-reactivity between GLP-1 receptor agonists is unknown (Ref). Until further studies are available, semaglutide should be used with caution in patients with a history of anaphylaxis or angioedema to other GLP-1 receptor agonists. Skin tests have been used in patients with histories of immediate hypersensitivity reactions (Ref) and delayed hypersensitivity reactions (Ref).
In the early stages of drug development, thyroid C-cell tumors were noted to have developed during animal studies with semaglutide. It is unknown whether semaglutide causes thyroid C-cell tumors in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. According to the manufacturer, human cases of medullary thyroid carcinoma (MTC) have been reported with liraglutide, another glucagon-like peptide-1 (GLP-1) receptor agonist.
Mechanism: Unknown; animal studies have shown dose-dependent and treatment duration-dependent harmful effects in rodents but not primates, thereby indicating that proliferative C-cell effects of liraglutide may be rodent specific. Humans have far fewer C cells than rodents, and expression of the GLP-1 receptor in human C cells is very low (Ref).
Risk factors:
• Patients with a personal or family history of MTC or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2) may be at an increased risk
Cases of acute pancreatitis (including hemorrhagic pancreatitis and necrotizing pancreatitis with some fatalities), chronic pancreatitis, and pancreatic adenocarcinoma have been reported with use of incretin-based therapies (eg, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide-1 [GLP-1] receptor agonists) (Ref). Acute pancreatitis was observed with semaglutide at rates similar to placebo during the SUSTAIN-6 trial (Ref).
Mechanism: Causality has not been firmly established (Ref). GLP-1 receptor agonists directly stimulate GLP-1 receptors in pancreatic islet beta cells and exocrine duct cells, which may cause an overgrowth of the cells that cover the smaller ducts, thereby resulting in hyperplasia, increased pancreatic weight, duct occlusion, back pressure, and subsequent acute or chronic pancreatic inflammation (Ref).
Onset: Not well characterized.
Risk factors:
• Patients with a prior history of pancreatitis may be at an increased risk for acute pancreatitis
• Patients with acute pancreatitis due to any cause are at an increased risk for progression to recurrent acute pancreatitis and then to chronic pancreatitis; patients with chronic pancreatitis are at an increased risk for pancreatic cancer (Ref)
• Risk factors for pancreatitis due to any cause include, but are not limited to, hypertriglyceridemia, cholelithiasis, alcohol use, and obesity
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults, unless otherwise noted.
>10%:
Gastrointestinal: Abdominal pain (adolescents and adults: 6% to 20%) (table 1), constipation (oral: 5% to 6%; SUBQ: adolescents: 6%; adults: 3% to 24%) (table 2), diarrhea (oral: 9% to 10%; SUBQ: adolescents and adults: 9% to 30%) (table 3), nausea (oral: 11% to 20%; SUBQ: adolescents and adults: 16% to 44%) (table 4), vomiting (oral: 6% to 8%; SUBQ: adolescents: 36%, adults: 5% to 24%) (table 5)
|
Drug (Semaglutide) |
Placebo |
Population |
Dose |
Dosage Form |
Number of Patients (Semaglutide) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|
|
15% |
6% |
Adolescents |
2.4 mg/week |
SUBQ |
133 |
67 |
|
20% |
10% |
Adults |
2.4 mg/week |
SUBQ |
2,116 |
1,261 |
|
11% |
4% |
Adults |
14 mg/day |
Oral |
356 |
362 |
|
10% |
4% |
Adults |
7 mg/day |
Oral |
356 |
362 |
|
7% |
5% |
Adults |
0.5 mg/week |
SUBQ |
260 |
262 |
|
6% |
5% |
Adults |
1 mg/week |
SUBQ |
261 |
262 |
|
Drug (Semaglutide) |
Placebo |
Population |
Dose |
Dosage Form |
Number of Patients (Semaglutide) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|
|
6% |
2% |
Adolescents |
2.4 mg/week |
SUBQ |
133 |
67 |
|
24% |
11% |
Adults |
2.4 mg/week |
SUBQ |
2,116 |
1,261 |
|
6% |
2% |
Adults |
7 mg/day |
Oral |
356 |
362 |
|
5% |
2% |
Adults |
14 mg/day |
Oral |
356 |
362 |
|
5% |
2% |
Adults |
0.5 mg/week |
SUBQ |
260 |
262 |
|
3% |
2% |
Adults |
1 mg/week |
SUBQ |
261 |
262 |
|
Drug (Semaglutide) |
Placebo |
Population |
Dose |
Dosage Form |
Number of Patients (Semaglutide) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|
|
22% |
19% |
Adolescents |
2.4 mg/week |
SUBQ |
133 |
67 |
|
30% |
16% |
Adults |
2.4 mg/week |
SUBQ |
2,116 |
1,261 |
|
10% |
4% |
Adults |
14 mg/day |
Oral |
356 |
362 |
|
9% |
4% |
Adults |
7 mg/day |
Oral |
356 |
362 |
|
9% |
2% |
Adults |
0.5 mg/week |
SUBQ |
260 |
262 |
|
9% |
2% |
Adults |
1 mg/week |
SUBQ |
261 |
262 |
|
Drug (Semaglutide) |
Placebo |
Population |
Dose |
Dosage Form |
Number of Patients (Semaglutide) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|
|
42% |
18% |
Adolescents |
2.4 mg/week |
SUBQ |
133 |
67 |
|
44% |
16% |
Adults |
2.4 mg/week |
SUBQ |
2,116 |
1,261 |
|
20% |
6% |
Adults |
1 mg/week |
SUBQ |
261 |
262 |
|
20% |
6% |
Adults |
14 mg/day |
Oral |
356 |
362 |
|
16% |
6% |
Adults |
0.5 mg/week |
SUBQ |
260 |
262 |
|
11% |
6% |
Adults |
7 mg/day |
Oral |
356 |
362 |
|
Drug (Semaglutide) |
Placebo |
Population |
Dose |
Dosage Form |
Number of Patients (Semaglutide) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|
|
36% |
10% |
Adolescents |
2.4 mg/week |
SUBQ |
133 |
67 |
|
24% |
6% |
Adults |
2.4 mg/week |
SUBQ |
2,116 |
1,261 |
|
9% |
2% |
Adults |
1 mg/week |
SUBQ |
261 |
262 |
|
8% |
3% |
Adults |
14 mg/day |
Oral |
356 |
362 |
|
6% |
3% |
Adults |
7 mg/day |
Oral |
356 |
362 |
|
5% |
2% |
Adults |
0.5 mg/week |
SUBQ |
260 |
262 |
Nervous system: Fatigue (SUBQ: 11%), headache (SUBQ: adolescents and adults: 14% to 17%)
Respiratory: Nasopharyngitis (SUBQ: adolescents: 12%)
1% to 10%:
Cardiovascular: Hypotension (SUBQ: adolescents and adults: 1% to 2%; including orthostatic hypotension)
Dermatologic: Alopecia (SUBQ: adolescents and adults: 3% to 4%), skin rash (SUBQ: adolescents: 3%), urticaria (SUBQ: adolescents: 3%)
Endocrine & metabolic: Diabetic retinopathy (complications: 3% to 7%; vitreous hemorrhage: 1%; blindness: <1%) (Ref), hypoglycemia (SUBQ: 2% to 6%), severe hypoglycemia (≤1%)
Gastrointestinal: Abdominal distension (2% to 7%), cholelithiasis (adolescents and adults: 0% to 4%) (table 6), decreased appetite (oral: 6% to 9%) (table 7), dysgeusia (SUBQ: ≤2%), dyspepsia (oral: 0.6% to 3%; SUBQ: 3% to 9%) (table 8), eructation (adolescents and adults: ≤7%), flatulence (1% to 6%), gastritis (2% to 4%), gastroenteritis (SUBQ: adolescents and adults: 6% to 7%), gastroesophageal reflux disease (adolescents and adults: 2% to 5%), viral gastroenteritis (SUBQ: 4%)
|
Drug (Semaglutide) |
Placebo |
Population |
Dose |
Dosage Form |
Number of Patients (Semaglutide) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|
|
4% |
0% |
Adolescents |
2.4 mg/week |
SUBQ |
133 |
67 |
|
2% |
0.7% |
Adults |
2.4 mg/week |
SUBQ |
2,116 |
1,261 |
|
2% |
0% |
Adults |
0.5 mg/week |
SUBQ |
260 |
262 |
|
1% |
0% |
Adults |
7 mg/day |
Oral |
356 |
362 |
|
0.4% |
0% |
Adults |
1 mg/week |
SUBQ |
261 |
262 |
|
0% |
0% |
Adults |
14 mg/day |
Oral |
356 |
362 |
|
Drug (Semaglutide) |
Placebo |
Population |
Dose |
Dosage Form |
Number of Patients (Semaglutide) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|
|
9% |
1% |
Adults |
14 mg/day |
Oral |
356 |
362 |
|
6% |
1% |
Adults |
7 mg/day |
Oral |
356 |
362 |
|
Drug (Semaglutide) |
Placebo |
Population |
Dose |
Dosage Form |
Number of Patients (Semaglutide) |
Number of Patients (Placebo) |
|---|---|---|---|---|---|---|
|
9% |
3% |
Adults |
2.4 mg/week |
SUBQ |
2,116 |
1,261 |
|
4% |
2% |
Adults |
0.5 mg/week |
SUBQ |
260 |
262 |
|
3% |
2% |
Adults |
1 mg/week |
SUBQ |
261 |
262 |
|
3% |
0.6% |
Adults |
7 mg/day |
Oral |
356 |
362 |
|
0.6% |
0.6% |
Adults |
14 mg/day |
Oral |
356 |
362 |
Genitourinary: Urinary tract infection (SUBQ: adolescents: 4%), urolithiasis (SUBQ: 1%)
Hepatic: Increased serum alanine aminotransferase (SUBQ: adolescents: 3%)
Immunologic: Antibody development (≤3%)
Infection: Influenza (SUBQ: adolescents: 3%)
Nervous system: Anxiety (SUBQ: adolescents: 4%), dizziness (SUBQ: adolescents and adults: 8%), dysesthesia (SUBQ: 2%; including allodynia, burning sensation, hyperesthesia, paresthesia)
Neuromuscular & skeletal: Bone fracture (SUBQ: 1% to 2%), sprain (ligament: SUBQ: adolescents: 4%)
Respiratory: Sinusitis (SUBQ: adolescents: 4%)
<1%:
Gastrointestinal: Acute pancreatitis (including hemorrhagic pancreatitis, necrotizing pancreatitis) (Ref), cholecystitis (SUBQ: adolescents and adults)
Local: Discomfort at injection site (SUBQ), erythema at injection site (SUBQ)
Frequency not defined: Gastrointestinal: Hemorrhoids (SUBQ), hiccups (SUBQ), increased serum amylase (adolescents and adults: mean increase from baseline of 10% to 16%), increased serum lipase (adolescents and adults: mean increase from baseline of 22% to 39%)
Postmarketing (any formulation or population):
Cardiovascular: Increased heart rate (Ref)
Dermatologic: Bullous pemphigoid (Ref)
Gastrointestinal: Biliary tract disease (Ref), cholecystectomy, delayed gastric emptying (Ref), gallbladder disease (Ref), intestinal obstruction
Hepatic: Hepatic injury (increased serum alkaline phosphatase, jaundice, and biliary cirrhosis) (Ref)
Hypersensitivity: Anaphylaxis (Ref), angioedema (Ref)
Renal: Acute interstitial nephritis (Ref), acute kidney injury (Ref)
Hypersensitivity to semaglutide or any component of the formulation; personal or family history of medullary thyroid carcinoma (MTC); patients with multiple endocrine neoplasia syndrome type 2 (MEN2)
Canadian labeling: Additional contraindications (not in US labeling): Pregnancy; breastfeeding
Concerns related to adverse effects:
• Psychiatric effects: Suicidal behavior has been reported with other medications used for weight management. Avoid use in patients with history of suicidal attempts or active suicidal ideation.
Disease-related concerns:
• Bariatric surgery:
- Dehydration: Evaluate, correct, and maintain postsurgical fluid requirements and volume status prior to initiating therapy, and closely monitor the patient for the duration of therapy; acute and chronic kidney failure exacerbation may occur. A majority of cases occurred in patients with nausea, vomiting, diarrhea, and/or dehydration. Nausea is common and fluid intake may be more difficult after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020).
- Excessive glucagon-like peptide-1 exposure: Closely monitor for efficacy and assess for signs and symptoms of pancreatitis if therapy is initiated after surgery; gastric bypass and sleeve gastrectomy (but not gastric band) significantly increase endogenous postprandial GLP-1 concentrations (Korner 2009; Peterli 2012). Administration of exogenous GLP-1 agonists may be redundant to surgery effects.
Concurrent drug therapy issues:
• Delayed gastric emptying: Semaglutide slows gastric emptying, which may alter the absorption of other medications. Monitor narrow therapeutic index medications for increased or decreased response.
Dosage form specific issues:
• Multiple dose injection pens (Ozempic): According to the CDC, pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC 2012).
Other warnings/precautions:
• Appropriate use:
- Diabetes mellitus: Do not use in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; not a substitute for insulin.
- Weight loss: Safety and effectiveness in combination with other products intended for weight loss have not been established.
• Surgical and endoscopic procedures: Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) has been associated with elevated residual gastric contents, which may increase the risk for adverse events during anesthesia and deep sedation (including aspiration) (Kobori 2023; Marroquin-Harris 2023; Silveira 2023). In some studies, delayed gastric emptying induced by GLP-1 RAs returned to baseline after 8 to 12 weeks of continuous therapy; therefore, risk may be higher in patients who recently initiated therapy or who use GLP-1 RAs intermittently (Raven 2024; van Zuylen 2024). Although the American Society of Anesthesiologists has suggested holding GLP-1 RAs prior to planned procedures requiring general anesthesia, the risks and benefits of this approach have not been evaluated (AGA [Hashash 2023]; ASA [Joshi 2023]). For example, in patients using GLP-1 RAs for glycemic control, holding the medication may result in perioperative hyperglycemia and increase the risk of adverse postoperative outcomes (AGA [Hashash 2023]; van Zuylen 2024). Individualize the decision to hold the GLP-1 RA based on patient-specific factors such as the indication (eg, glycemic control vs weight management), duration and frequency of therapy, presence of adverse GI symptoms, and concomitant medications that may slow gastric emptying (eg, opioids, proton pump inhibitors); may consider additional preoperative interventions (eg, clear liquid diet, full stomach precautions, gastric ultrasound) on a case-by-case basis to reduce risk (ASA [Hashash 2023]; Marroquin-Harris 2023; Raven 2024; van Zuylen 2024). Refer also to institutional protocols.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution Auto-injector, Subcutaneous:
Wegovy: 0.25 mg/0.5 mL (0.5 mL); 0.5 mg/0.5 mL (0.5 mL); 1 mg/0.5 mL (0.5 mL); 1.7 mg/0.75 mL (0.75 mL); 2.4 mg/0.75 mL (0.75 mL)
Solution Pen-injector, Subcutaneous:
Ozempic (0.25 or 0.5 MG/DOSE): 2 mg/3 mL (3 mL); 0.25 mg or 0.5 mg per dose [2 mg/1.5 mL] (1.5 mL [DSC]) [contains phenol, propylene glycol]
Ozempic (1 MG/DOSE): 1 mg per dose [4 mg/3 mL] (3 mL); 1 mg per dose [2 mg/1.5 mL] (1.5 mL [DSC]) [contains phenol, propylene glycol]
Ozempic (2 MG/DOSE): 8 mg/3 mL (3 mL) [contains phenol, propylene glycol]
Tablet, Oral:
Rybelsus: 3 mg, 7 mg, 14 mg
No
Solution Auto-injector (Wegovy Subcutaneous)
0.25 mg/0.5 mL (per 0.5 mL): $404.71
0.5 mg/0.5 mL (per 0.5 mL): $404.71
1 mg/0.5 mL (per 0.5 mL): $404.71
1.7 mg/0.75 mL (per 0.75 mL): $404.71
2.4 mg/0.75 mL (per 0.75 mL): $404.71
Solution Pen-injector (Ozempic (0.25 or 0.5 MG/DOSE) Subcutaneous)
2 mg/3 mL (per mL): $387.41
Solution Pen-injector (Ozempic (1 MG/DOSE) Subcutaneous)
4 mg/3 mL (per mL): $387.41
Solution Pen-injector (Ozempic (2 MG/DOSE) Subcutaneous)
8 mg/3 mL (per mL): $387.41
Tablets (Rybelsus Oral)
3 mg (per each): $38.74
7 mg (per each): $38.74
14 mg (per each): $38.74
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution Pen-injector, Subcutaneous:
Ozempic (0.25 or 0.5 MG/DOSE): 2 mg/3 mL (3 mL); 0.25 mg or 0.5 mg per dose [2 mg/1.5 mL] (1.5 mL) [contains phenol, propylene glycol]
Ozempic (1 MG/DOSE): 1 mg per dose [4 mg/3 mL] (1.5 mL) [contains phenol, propylene glycol]
Wegovy: 0.5 mg/dose (1.5 mL); 1 mg/dose (3 mL); 1.7 mg/dose (3 mL); 2.4 mg/dose (3 mL) [contains phenol, propylene glycol]
Tablet, Oral:
Rybelsus: 3 mg, 7 mg, 14 mg
SUBQ: Wegovy: Administer by SUBQ injection into the abdomen (do not inject within 2 inches of belly button), thigh, or upper arm at any time of day on the same day each week, with or without food. Solution should be clear; do not use if particulate matter and coloration are seen; do not mix with other products. After removal of the pen cap, the needle will be hidden inside the needle cover. To begin injection, press the needle cover firmly against the skin, continue to press the device against the skin until the yellow bar has stopped moving. Then, slowly remove the needle from the skin and dispose of pen. Rotate injection sites weekly if injecting in the same area of the body. Do not inject into areas that are tender, bruised, red, or hard, or have scars or stretch marks. If changing the day of administration is necessary, allow ≥2 days between 2 doses.
Missed doses: If one dose is missed and the next scheduled dose is >2 days away, administer the missed dose as soon as possible. If one dose is missed and the next scheduled dose is <2 days away, do not administer the missed dose and resume dosing on the regularly scheduled day of the week. If 2 or more doses are missed, may either resume at the next regularly scheduled day of the week or may consider reinitiating semaglutide and follow the dose escalation schedule.
Oral: Administer on an empty stomach, ≥30 minutes before the first food, beverage, or other oral medications of the day with ≤4 oz of plain water only. The manufacturer recommends eating 30 to 60 minutes after the dose. Swallow tablets whole; do not split, crush, or chew.
SUBQ: Administer by SUBQ injection into the abdomen, thigh, or upper arm at any time of day on the same day each week, with or without food. If changing the day of administration is necessary, allow ≥48 hours between 2 doses. Rotate injection sites weekly if injecting in the same area of the body. Do not mix with other products (administer as separate injections). Avoid adjacent injections if administering other agents in the same area of the body. Solution should be clear; do not use if particulate matter and coloration are seen.
Ozempic: For each new prefilled pen, prime the needle before the first injection by turning the dose selector to the flow check symbol and injecting into the air (priming is not required for subsequent injections). Use a new needle for each injection. Once injected, continue to depress the button until the dial has returned to 0 and for an additional 6 seconds. Then, remove the needle from the skin.
Wegovy: After removal of the pen cap, the needle will be hidden inside the needle cover. To begin injection, press the needle cover firmly against the skin. Once injected, continue to press the device against the skin until the yellow bar has stopped moving. Then, remove the needle from the skin.
This medication is not on the National Institute for Occupational Safety and Health (NIOSH) (2016) list; however, it may meet the criteria for a hazardous drug. Semaglutide may cause carcinogenicity, teratogenicity, and reproductive toxicity.
Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations and institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).
Note: Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.
Injection:
Ozempic pen: Prior to initial use, store at 2°C to 8°C (36°F to 46°F). After initial use, store at 2°C to 8°C (36°F to 46°F) or 15°C to 30°C (59°F to 86°F) for up to 56 days; discard after 56 days. Do not freeze (discard if freezing occurs) or store directly adjacent to the refrigerator cooling element. Protect from excessive heat and sunlight. Keep pen capped when not in use.
Wegovy pen: Store at 2°C to 8°C (36°F to 46°F). If needed, prior to cap removal, the pen can be kept from 8°C to 30°C (46°F to 86°F) up to 28 days. Do not freeze; protect from light. Keep in original carton until time of administration; discard pen after use (for single use only).
Wegovy FlexTouch [Canadian product]: Store at 2°C to 8°C (36°F to 46°F). After initial use, store at 2°C to 30°C (36°F to 86°F) for up to 8 weeks. Protect from light. Keep pen capped when not in use.
Oral: Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Store in original blister card; protect from moisture.
An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:
Ozempic: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/209637s012lbl.pdf#page=27
Rybelsus: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213051s018lbl.pdf#page=24
Wegovy: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf#page=35
Adjunct treatment for chronic weight management along with a reduced-calorie diet and increased physical activity in pediatric patients with an initial BMI in the ≥95th percentile standardized for age and sex (Injection: Wegovy: FDA approved in pediatric patients ≥12 years of age); adjunct treatment for chronic weight management along with a reduced-calorie diet and increased physical activity in patients with either an initial BMI of ≥30 kg/m2 or an initial BMI of ≥27 kg/m2 and at least one weight-related comorbid condition (eg, dyslipidemia, type 2 diabetes mellitus, hypertension) (Injection: Wegovy: FDA approved in adults); as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus (Injection: Ozempic, Oral: Rybelsus: FDA approved in adults); risk reduction of major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in patients with type 2 diabetes mellitus and established cardiovascular disease (Injection: Ozempic, Wegovy: FDA approved in adults).
Cross-contamination may occur if pens are shared among multiple patients. Steps should be taken to prohibit sharing of pens.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy
Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy
Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy
Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy
Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy
Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy
Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy
Furosemide: May diminish the therapeutic effect of Semaglutide. Semaglutide may increase the serum concentration of Furosemide. Risk C: Monitor therapy
Glucagon-Like Peptide-1 Agonists: Semaglutide may enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists. Risk X: Avoid combination
Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy
Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy
Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy
Insulins: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Insulins. Management: Consider insulin dose reductions when used in combination with glucagon-like peptide-1 agonists. Monitor patients for hypoglycemia. Risk D: Consider therapy modification
Levothyroxine: Semaglutide may increase the serum concentration of Levothyroxine. Risk C: Monitor therapy
Liraglutide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists. Risk X: Avoid combination
Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy
Meglitinides: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Meglitinides. Management: Consider meglitinide dose reductions when used in combination with glucagon-like peptide-1 agonists, particularly when also used with basal insulin. Risk D: Consider therapy modification
Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy
Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy
Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy
Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy
Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy
Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy
Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy
Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification
Sulfonylureas: Glucagon-Like Peptide-1 Agonists may enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists. Risk D: Consider therapy modification
Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy
Tirzepatide: May enhance the adverse/toxic effect of Glucagon-Like Peptide-1 Agonists. Risk X: Avoid combination
Oral: Administer on an empty stomach, ≥30 minutes before the first food, beverage, or other oral medications of the day with ≤4 oz of plain water only. The manufacturer recommends eating 30 to 60 minutes after the dose.
Glucagon-like peptide-1 (GLP-1) receptor agonists are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)
When used for the treatment of diabetes mellitus or weight loss management, semaglutide should be discontinued for ≥2 months prior to becoming pregnant.
Medications for weight loss therapy are not recommended at conception (ACOG 2021).
Poorly controlled diabetes during pregnancy is associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia (ACOG 2018). To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023).
Agents other than semaglutide are currently recommended to treat diabetes mellitus during pregnancy (ADA 2023).
An increased risk of adverse maternal and fetal outcomes is associated with obesity; however, medications for weight loss therapy are not recommended during pregnancy (ACOG 2021).
Data collection to monitor pregnancy and infant outcomes following exposure to semaglutide is ongoing. Health care providers are encouraged to enroll patients exposed to semaglutide during pregnancy in the registry by contacting Novo Nordisk (1-877-390-2760 or https://www.wegovypregnancyregistry.com). Patients may also enroll themselves.
Chronic weight management parameters, heart rate, renal function (especially when initiating therapy or increasing doses in patients reporting severe adverse GI reactions); signs/symptoms of pancreatitis (eg, persistent severe abdominal pain, which may radiate to the back and which may or may not be accompanied by vomiting); triglycerides; signs/symptoms of gallbladder disease; signs/symptoms of hypersensitivity; monitor for depression, clinical worsening, suicidality, or unusual changes in behavior.
Semaglutide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist that increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, slows gastric emptying; also acts in the areas of the brain involved in regulation of appetite and caloric intake.
Distribution: Vd: Oral: ~8 L; SUBQ: ~12.5 L.
Protein binding: >99% to albumin.
Metabolism: Proteolytic cleavage of the peptide backbone with sequential beta-oxidation of the fatty acid sidechain.
Bioavailability: Oral: ~0.4% to 1%; SUBQ: 89%.
Half-life elimination: ~1 week.
Time to peak, plasma: Oral: 1 hour; SUBQ: 1 to 3 days.
Excretion: Urine (~3% as unchanged drug), feces.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
